Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

The Netherlands Food and Consumer Product Safety Authority (NVWA) has issued another recall over potential E.coli ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...

An E coli infection linked to the death of a doctor in Princess Margaret Hospital is unlikely to lead to widespread ...

During an inspection, E. coli was found at 1,000 times the legal limit in Crosby, Texas, roughly 30 minutes northeast of Houston. Although the contaminated water isn't getting into the region's ...

The Centre for Health Protection is looking into a suspected Shiga toxin-producing Escherichia coli infection cluster ...

Diarrheagenic E. coli (DEC) is a major global cause of diarrheal diseases, with certain strains showing alarming levels of antibiotic resistance.